X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GDA-201 is an intrinsic NK cell therapy candidate being investigated for the treatment of hematologic malignancies. A multicenter Phase 1 study of GDA-201 for the treatment of non-Hodgkin lymphoma is ongoing. Results are expected in Q1 2024.
Lead Product(s): GDA-201
Therapeutic Area: Oncology Product Name: GDA-201
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
Gamida Cell intends to use the net proceeds to fund the commercialization activities to support the launch of Omisirge (omidubicel-onlv) and the continued clinical development of GDA-201.
Lead Product(s): Omidubicel-onlv
Therapeutic Area: Oncology Product Name: Omisirge
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Piper Sandler & Co.
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 19, 2023
Details:
Omisirge (omidubicel-onlv) ,FDA approved, is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy,it is indicated for hematologic malignancies who are planned for umbilical cord blood transplantation.
Lead Product(s): Omidubicel-onlv
Therapeutic Area: Oncology Product Name: Omisirge
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
NiCord (omidubicel) is an advanced cell therapy candidate developed as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant for patients with blood cancers.
Lead Product(s): Omidubicel
Therapeutic Area: Oncology Product Name: NiCord
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Highbridge Capital Management
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing December 12, 2022
Details:
NiCord (omidubicel) is an advanced cell therapy candidate developed as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant for patients with blood cancers.
Lead Product(s): Omidubicel
Therapeutic Area: Oncology Product Name: NiCord
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Details:
If approved, NiCord (omidubicel) is projected to have meaningful improvement in patient outcomes among racial and ethnic minorities by potentially extending access to allogeneic hematopoietic cell transplant (allo-HCT) and reducing time to transplant.
Lead Product(s): Omidubicel
Therapeutic Area: Oncology Product Name: NiCord
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
GDA-201 leverages Gamida Cell’s proprietary NAM (nicotinamide) technology platform to expand the number and functionality of NK cells to direct tumor cell killing properties and antibody-dependent cellular cytotoxicity (ADCC).
Lead Product(s): NAM-expanded Allogeneic NK Cells
Therapeutic Area: Oncology Product Name: GDA-201
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
NiCord (omidubicel) is an advanced cell therapy candidate developed as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant for patients with blood cancers.
Lead Product(s): Omidubicel
Therapeutic Area: Oncology Product Name: NiCord
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
NiCord (omidubicel) is a first-in-class, advanced NAM-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of transplant.
Lead Product(s): Omidubicel
Therapeutic Area: Oncology Product Name: NiCord
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
In study, GDA-201 was well-tolerated and no dose-limiting toxicities were observed in 19 patients with NHL and 16 patients with multiple myeloma, also demonstrated a median duration of response of 16 months and overall survival at two years of 78%.
Lead Product(s): NAM-expanded Allogeneic NK Cells
Therapeutic Area: Oncology Product Name: GDA-201
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
